找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

123456
返回列表
打印 上一主題 下一主題

Titlebook: Viral Drug Delivery Systems; Advances in Treatmen Ranjita Shegokar,Yashwant Pathak Book 2023 The Editor(s) (if applicable) and The Author(s

[復(fù)制鏈接]
樓主: 出租
51#
發(fā)表于 2025-3-30 11:35:29 | 只看該作者
COVID-19: Molecular Pathogenesis and Prospective Therapeutic Interventions, the world health organization (WHO). The pathogen (SARS-CoV-2) targets the epithelial cells of the respiratory system, resulting in diffuse alveolar damage. Here, in this chapter, we have comprehensively reviewed the information regarding SARS-CoV-2 infections, its molecular basis of pathogenesis,
52#
發(fā)表于 2025-3-30 12:35:23 | 只看該作者
Exploring the Link Between Malaria and COVID-19,th limited per capita income..As the discussion in this article will show, the difference in the prevalence of COVID-19 among populations is correlated uneven propagation of the ACEI/D and the ACE2 (C1173T substitution) polymorphisms. The similarity of presentations between . and COVID-19 and the po
53#
發(fā)表于 2025-3-30 19:31:14 | 只看該作者
The Use of Azithromycin and Lopinavir-Ritonavir in the Treatment of COVID-19,hrough both in vitro and clinical trials; the results of which have confirmed its potential application as part of COVID-19 treatment therapy. In vitro tests conducted on Vero cells indicated that a combination of lopinavir/ritonavir and azithromycin is highly effective in inhibiting viral replicati
54#
發(fā)表于 2025-3-31 00:32:37 | 只看該作者
Current Strategies to Combat COVID-19,he article. Currently used therapeutics for COVID-19 like remdesivir, chloroquine, and hydroxychloroquine, lopinavir/ritonavir, ribavirin, favipiravir, Arbidol, convalescent plasma therapy are discussed.
55#
發(fā)表于 2025-3-31 04:08:45 | 只看該作者
Phytomolecules and Novel Drug Delivery Approach for COVID-19, natural phytoconstituents are efficient home remedies for COVID-19 therapy for quick recovery and immune modulators as a preventive measure. In this chapter, we’ve discussed the value of natural substances in the treatment of COVID-19 as well as contemporary integrated pharmaceutical therapies that
56#
發(fā)表于 2025-3-31 07:20:08 | 只看該作者
57#
發(fā)表于 2025-3-31 09:32:56 | 只看該作者
58#
發(fā)表于 2025-3-31 16:27:21 | 只看該作者
123456
返回列表
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 16:22
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
景谷| 城口县| 赫章县| 大新县| 盘山县| 清河县| 南漳县| 盐津县| 桐庐县| 营山县| 涪陵区| 柳江县| 阿克陶县| 东阳市| 博野县| 定襄县| 新晃| 清河县| 修文县| 定陶县| 本溪市| 黔西| 江永县| 乌拉特后旗| 芦山县| 德清县| 阜康市| 谷城县| 西林县| 交城县| 固镇县| 海阳市| 彭山县| 剑川县| 汾阳市| 通榆县| 三门峡市| 永平县| 眉山市| 宜章县| 桃江县|